Hyderabad Telangana, India

Dharmender Ragidi

This inventor holds 2 USPTO granted patents. Top assignee: Natco Pharma Limited. Active years: 2020-2022.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2020-2022

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Dharmender Ragidi: Innovator in Pharmaceutical Processes

Introduction

Dharmender Ragidi is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of processes for drug preparation. With a total of two patents to his name, Ragidi's work showcases his expertise and dedication to innovation in the pharmaceutical industry.

Latest Patents

Ragidi's latest patents include a process for the preparation of Tipiracil hydrochloride and intermediates thereof. This invention provides a method for producing Tipiracil HCl with improved yields and purities. Additionally, he has developed a process for the preparation of dasatinib polymorph, which relates to an improved method for obtaining dasatinib in anhydrous crystalline form with high purity and yield. This invention also addresses the purification of dasatinib crystalline Neat form N-6.

Career Highlights

Dharmender Ragidi is currently associated with Natco Pharma Limited, where he applies his innovative skills to advance pharmaceutical processes. His work has contributed to the company's reputation for quality and efficacy in drug development.

Collaborations

Ragidi collaborates with talented professionals in his field, including Srinivasulu Sakkani and Uma Naresh Babu Kotra. These collaborations enhance the innovative capacity of their projects and contribute to the success of their endeavors.

Conclusion

Dharmender Ragidi is a prominent inventor whose work in pharmaceutical processes has led to significant advancements in drug preparation. His contributions are vital to the ongoing development of effective medications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…